Funding for this research was provided by:
Guarantors of Brain
National Institute for Health Research
Received: 14 September 2021
Accepted: 12 January 2022
First Online: 29 January 2022
: Unrelated to the work PJG reports, over the last 36 months, grants and personal fees from Amgen and Eli-Lilly and Company, grant from Celgene, and personal fees from Aeon Biopharma, Allergan, Biohaven Pharmaceuticals Inc., Clexio, Electrocore LLC, eNeura, Epalex, GlaxoSmithKline, Impel Neuropharma, Lundbeck, MundiPharma, Novartis, Pfizer, Praxis, Sanofi, Santara Therapeutics, Satsuma, Teva Pharmaceuticals, Trigemina Inc., and personal fees for advice through Gerson Lehrman Group and Guidepoint, fees for educational materials from Massachusetts Medical Society, Medery, Medlink, PrimeEd, UptoDate, WebMD, and publishing royalties from Oxford University Press, and Wolters Kluwer, and for medicolegal advice in headache, and a patent magnetic stimulation for headache (No. WO2016090333 A1) assigned to eNeura without fee.
: This study was conducted with the aim of increasing the quality of our symptom capture and history taking among our clinical patients (a quality improvement project), and therefore no specific ethical approval or consent to participate was sought. Subject consent was therefore not acquired prior to preparation of this manuscript.
: The authors declare no competing interests related to this work.